Table 1.

Summarization of post-AstraZeneca vaccination Guillain-Barre syndrome cases.

Names of Authors	Country/region	Case no.	Age/ ethnicity	1st/ 2nd dose	Time of Sx onset	Tx
[5] Patel SU, et al, 2021	England	1 case	37 y/o male, Caucasian	1st	14 d	5 d of IVIG
[6] Maramattom BV, et al, 2021	Kerala, India	7 cases	All of Indian descent: 1) 43 y/o female 2) 67 y/o female 3) 53 y/o female 4) 68 y/o female 5) 70 y/o male 6) 69 y/o female 7) 69 y/o female	1st	1) 10 d 2) 14 d 3) 12 d 4) 14 d 5) 11 d 6) 12 d 7) 13 d	1) IVIG + mechanical ventilation 2) IVIG+ mechanical ventilation+ plasmapheresis 3) IVIG + mechanical ventilation 4) IVIG + mechanical ventilation 5) IVIG+ mechanical ventilation 6) IVIG + plasmapheresis 7) IVIG + mechanical ventilation
[7] Allen CM, et al, 2021	England	4 cases	1) 54 y/o male, Caucasian 2) 20 y/o male, British Iranian descent 3) 57 y/o male, Caucasian 4) 55 y/o male, Caucasian	1st	1) 16 d 2) 26 d 3) 21 d 4) 29 days	1) Oral prednisolone 2) Oral prednisolone 3) IVIG 4) No treatment needed
[8] Hasan T, et al, 2021	England	1 case	62 y/o female, ethnicity unknown	1st	11 d	IVIG + mechanical ventilation + intravenous antibiotics (for secondary sepsis due to aspiration pneumonia)
[9] Nasuelli NA, et al, 2021	Italy	1 case	59 y/o male, Caucasian	1st	10 d	IVIG
[10] McKean N, et al, 2021	Malta	1 case	48 y/o male, presumed Maltese	1st	10 d	IVIG + oral prednisolone
Our case	Kaohsiung, Taiwan	1 case	48 y/o female, Japanese (East-Asian)	1st	14 d	IVIG

^∗ Intravenous immunoglobulin (IVIG).